The introduction of monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), program death protein 1 (PD-1), or lymphocyte activation gene-3 (LAG-3) dramatically changed the prognosis of patients with late-stage melanoma. Here, LAG3 is linked to melanoma.